Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
With the advancement of mechanistic research and the progression of clinical trials, the treatment of CRC is moving toward more personalized and precise approaches, thereby providing patients with more effective and safer treatment options
GHK-Cu, the tripeptide glycyl-L-histidyl-L-lysine bound to copper, demonstrates activity at concentrations that would seem impossibly small to anyone familiar with standard peptide dosing
Rather than treating ferroptosis as a uniform vulnerability, clinical translation will probably succeed where patients can be stratified by (1) the architecture of antioxidant defenses (for example, FSP1/GPX4 balance), (2) the size and distribution of cellular CoQ pools, (3) lipid composition and peroxidation-prone membranes and (4) oncogenic programs that remodel redox metabolism (such as NRF2KEAP1)
Should GHK-Cu be injected or applied topically
US$ 27.52
US$ 26.23
US$ 29.94
US$ 26.39
